<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369443">
  <stage>Registered</stage>
  <submitdate>6/11/2015</submitdate>
  <approvaldate>21/01/2016</approvaldate>
  <actrnumber>ACTRN12616000061437</actrnumber>
  <trial_identification>
    <studytitle>An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease</studytitle>
    <scientifictitle>A phase II trial comparing cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel in patients with inoperable locally recurrent or metastatic anal cancer to demonstrate which is more effective and less toxic for patients with this disease.</scientifictitle>
    <utrn />
    <trialacronym>InterAACT</trialacronym>
    <secondaryid>AG0214ANL</secondaryid>
    <secondaryid>NCT02051868</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Squamous Cell Carcinoma of the Anus</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Anal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Those randomised to the experimental arm will receive 6 cycles of chemotherapy within a 4 weekly schedule as follows:
Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each cycle followed by carboplatin 1-hour (or 30-min) i.v. infusion to an AUC of 5 on day 1, with the
initial dose calculated according to the Calvert formula (mg = [glomerular
filtration rate (GFR) + 25] x 5). The GFR used in the Calvert formula to calculate
AUC-based dosing should not exceed 125 ml/min.</interventions>
    <comparator>Participants randomised to the control arm will receive 8 cycles of chemotherapy within a 3 weekly schedule as follows:
Cisplatin 60 mg/m2 by iv infusion on day 1
5-Fluorouracil 1000 mg/m2/day - days 1-4 by continuous 24 hour iv infusion</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate best overall response rate (ORR) by 24 weeks post treatment in the cisplatin plus 5-fluorouracil (5-FU) arm versus the carboplatin plus weekly paclitaxel arm</outcome>
      <timepoint>Best overall response rate is defined as the percentage of patients achieving confirmed partial or complete responses as per RECIST v1.1 by 24 weeks post treatment start in the intention to treat population</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>PFS will be analysed once all patients have been followed up for at least 12 months post treatment start. This is calculated from the date of randomisation to the date of confirmed clinical/radiological progression or death from any cause. Patients who are lost to follow-up, withdraw from follow-up or alive and progression free will be censored at the date of last follow-up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival </outcome>
      <timepoint>Overall survival will be analysed once all patients have been followed up for at least 12 months post treatment start. This is calculated from the date of randomisation to the date of death from any cause. Patients, in whom no death is recorded, will be censored at the date they were last seen alive.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control rate (DCR) (stable disease (SD) or better) at 12 and 24 weeks</outcome>
      <timepoint>12 and 24 weeks post treatment start. Disease control rate is defined as complete response, partial response or stable disease, and will be assessed in accordance with the RECIST criteria v1.1.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best overall response rate of non-irradiated lesions</outcome>
      <timepoint>24 weeks post treatment start. Best overall response of non-irradiated lesions is defined as the percentage of patients achieving confirmed partial response or complete response as per RECIST v1.1 of non-irradiated sites of disease.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-tumour activity and magnitude of response as captured by waterfall plot analyses. Anti-tumour activity will be assessed by imaging (CT or MRI).</outcome>
      <timepoint>Anti-tumour activity and magnitude of response will be captured by waterfall plot analyses and indicate the percentage change in tumour size from baseline to the time of best response.  
Imaging (CT or MRI) will be performed at baseline and after 12 and 24 weeks of study treatment. In case the study treatment is continued for more than 24 weeks, tumour response will be assessed every 12 weeks. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>Toxicity will be analysed once all patients have been followed up for at least 4 weeks post treatment completion. Toxicity will be graded according to the NCI CTCAE Version 4.0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life </outcome>
      <timepoint>3 years. Quality of Life will be evaluated using the EORTC QLQ C30 and EQ-5D-5L questionnaires. The functional and symptomatic scales and global health status from the QLQ C30 and EQ-5D-5L questionnaire will be calculated as per EORTC and EuroQol guidelines, respectively.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Feasibility of conducting a multicentre, international study on squamous cell carcinoma of the anus and recruiting within a reasonable time frame. </outcome>
      <timepoint>3 years. The study will be conducted in approximately 50 international centres. This secondary endpoint will be measured by (i) the proportion of centres that successfully recruit at least one patient and (ii) overall recruitment rate. We anticipate and would be able to confirm feasibility if 80% of the centres fully engaged with the study. The aim would be to recruit 80 patients in 36 months (10 by month 6, 20 by month 12, 50 by month 24 and 80 by month 36).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Inoperable, locally recurrent or metastatic disease (tumour resectability should be assessed by a local surgeon or Multidisciplinary Team) 
-Histological or cytological confirmation of epidermoid anal carcinoma (includes squamous, basaloid and cloacogenic lesions) from the primary tumour or a newly diagnosed recurrent/metastatic lesion. 
-Age greater than or equal to 18 years.
-ECOG PS less than or equal to 2.
-Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1. 
-Previous definitive chemo-radiation is permitted for early stage tumours (cisplatin-based chemo-radiation is permitted but only if tumour progression/relapse occurs after 6 months from treatment completion).
-Previous systemic chemotherapy is permitted if administered as induction treatment (less than or equal to 2 cycles) before definitive chemoradiotherapy for early stage disease and there is no evidence of tumour progression during or after treatment completion.
-HIV positive patients will be considered eligible if they are on HAART and have a CD4 count of greater than or equal to 200/microlitre (HIV+ patients who are on HAART and have a CD4 count less than 200/microlitre are eligible if the plasma viral load is below the level of detection according to the local assay).
-Adequate cardiac and respiratory function; absolute neutrophil count (ANC) greater than or equal to 1.5x109/l; platelets greater than or equal to 100x109/l; haemoglobin (Hb) greater than or equal to 9g/dl for males and greater than or equal to 8g/dl for females; creatinine clearance greater than or equal to 50ml/minute; serum bilirubin less than or equal to 1.5x upper limit of normal (ULN); alanine transaminase (ALT) or aspartate transaminase (AST) less than or equal 3x ULN (If liver metastases are present, serum transaminases less than or equal 5x ULN are permitted.
-Fertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapy.
-Life expectancy of at least 3 months.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-Tumours of adenocarcinoma, melanoma, small cell and basal cell histology are excluded.
-Newly diagnosed locally advanced tumour which requires upfront systemic chemotherapy but is still amenable to curative treatment (i.e. chemotherapy followed by definitive chemoradiotherapy)
-Locally recurrent tumour which is amenable to curative resection (as deemed by a local surgeon or Multidisciplinary Team).
-Tumour relapse/progression within 6 months of completion of a cisplatin-based chemoradiotherapy regimen for the treatment of early stage tumours.   
-Previous administration of greater than 2 cycles of systemic chemotherapy as induction treatment before definitive chemoradiotherapy for early stage disease.
Tumour progression during or immediately after completion of less than or equal to 2 cycles of systemic chemotherapy as induction treatment before definitive chemoradiotherapy for early stage disease.
-Previous use of systemic chemotherapy or other investigational drugs for the treatment of inoperable locally recurrent or metastatic tumours (previous use of radiotherapy in this setting is not an exclusion criterion if: 1) non-irradiated target tumour lesions are present at randomisation for the purpose of tumour response assessment or 2) in the absence of non-irradiated target tumour lesions, progression of the irradiated tumour lesions according to the RECIST criteria version 1.1 is documented).
-Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study.
-Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease.
-Major surgery performed less than 28 days from treatment start.
-Palliative radiotherapy completed less than or equal to 7 days from treatment start.
-Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery disease, uncontrolled cardiac arrhythmia, or myocardial infarction within the last 6 months). Any history of clinically significant cardiac failure.
- History of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan.
- HIV positive patients who are not on HAART or have a CD4 count of less than 200/microlitre in the presence of detectable plasma viral load according to the local assay.
-Known history of active hepatitis B or hepatitis C infection.
-Serious active infection requiring i.v. antibiotics at enrolment.
-Other malignancy within the last 5 years, except for adequately treated carcinoma 	in situ of the cervix or squamous carcinoma of the skin, or adequately controlled 	limited basal cell skin cancer.
-Other clinically significant disease or co-morbidity that may adversely affect the safe delivery of treatment within this trial.
-Known hypersensitivity to any of the study drugs or excipients.
-Known peripheral neuropathy greater than grade 1 (absence of deep tendon reflexes as thesole neurological abnormality does not render the patient ineligible).
-Pre-existing hearing impairment.
-Patients planning for a live vaccine.
-Pregnant or lactating females.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>29/02/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC</recruitmentstate>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Gastro-Intestinal Trials Group (AGITG)</primarysponsorname>
    <primarysponsoraddress>Locked Bag 77 
Camperdown
NSW 1450</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Australasian Gastro-Intestinal Trials Group (AGITG)</fundingname>
      <fundingaddress>Locked Bag 77 
Camperdown
NSW 1450</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>The Royal Marsden NHS Foundation Trust</sponsorname>
      <sponsoraddress>Downs Road, Sutton, Surrey, SM2 5PT
United Kingdom</sponsoraddress>
      <sponsorcountry>United Kingdom</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to compare two different chemotherapy regimens for the treatment of inoperable, locally recurrent, or metastatic anal cancer to demonstrate which is more effective and less toxic for patients with this disease. 
Who is it for? You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with inoperable, locally recurrent or metastatic anal cancer. 
Study details: Participants in this study will be randomly allocated (by chance) to one of two groups. Participants in one group will receive chemotherapy treatment with cisplatin and 5-FU for 8 x 3 week cycles (about 24 weeks in total)  this is the most frequently prescribed chemotherapy for this condition. Participants in the other group will receive chemotherapy with carboplatin and paclitaxel in 6 x 4 week cycles (24 weeks in total). Both groups will receive their chemotherapy intravenously, i.e. given into a vein through a drip. All participants will be followed for up to 3 years post treatment in order to evaluate treatment response, toxicity and quality of life. This is the first time that a formal comparison of these chemotherapies has been performed.</summary>
    <trialwebsite />
    <publication>Francesco Sclafani, Richard A. Adams, Cathy Eng, Al Bowen Benson, Robert Glynne-Jones, David Sebag-Montefiore, Dirk Arnold, Amitesh Chandra Roy, Marianne Gr√∏nlie Guren, Eva Segelov, Matthew T. Seymour, Annette Bryant, Clare Peckitt, David Cunningham, John A. Bridgewater, Jack Welch, Peter J. O'Dwyer, Elisabeth Dupont, Andrea McConnell, Sheela Rao. InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease. Gastrointestinal Cancers Symposium; 1517 Jan 2015; San Francisco.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Sydney Local Health District Human Research Ethics Committee (NSLHD HREC)</ethicname>
      <ethicaddress>Research Office, Level 13 Kolling Building
Royal North Shore Hospital
St Leonards NSW 2065
</ethicaddress>
      <ethicapprovaldate>29/06/2015</ethicapprovaldate>
      <hrec>HREC/14/HAWKE/421</hrec>
      <ethicsubmitdate>24/11/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Amitesh C Roy </name>
      <address>NHMRC Clinical Trials Centre Locked Bag 77 Camperdown, NSW, 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>interAACT@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>InterAACT Trial Coordinator</name>
      <address>NHMCR CTC Locked Bag 77 Camperdown, NSW, 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>interAACT@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>InterAACT Trial Coordinator</name>
      <address>NHMCR CTC Locked Bag 77 Camperdown, NSW, 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>interAACT@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>InterAACT Trial Coordinator</name>
      <address>NHMCR CTC Locked Bag 77 Camperdown, NSW, 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>interAACT@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>